Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmatrix Inc PULM

Healthcare
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as... see more

Recent & Breaking News (NDAQ:PULM)

Pulmatrix Reports Q3 2018 Results

PR Newswire November 14, 2018

Pulmatrix to present pre-clinical data on PUR1800 (RV1162) at the European Respiratory Society International Congress

PR Newswire September 17, 2018

Pulmatrix to Present at the 20th Annual Rodman & Renshaw Global Investment Conference on September 5, 2018

PR Newswire August 28, 2018

Pulmatrix Reports Q2 2018 Results

PR Newswire August 3, 2018

Pulmatrix Announces the Formation of the Pulmazole Clinical Advisory Board to Support Future Development

PR Newswire July 23, 2018

Pulmatrix Announces Positive Top-Line Results from Parts 1 and 2 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

PR Newswire June 25, 2018

Pulmatrix Announces Publication of Results from a Phase 1 Pharmacodynamic Study of PUR0200 in COPD Patients

PR Newswire June 13, 2018

Pulmatrix Announces Approval of Proposals Submitted to Company's Stockholders

PR Newswire June 7, 2018

Pulmatrix selected to present company profile at the 2018 Respiratory Innovation Summit in San Diego

PR Newswire May 17, 2018

Pulmatrix Reports Q1 2018 Results

PR Newswire May 11, 2018

Pulmatrix to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017

PR Newswire September 21, 2017

Pulmatrix Receives Key Patents on its Inhaled Drug Delivery Technology and its COPD Drug

PR Newswire September 20, 2017

CEO Robert Clarke Discusses Positive Developments from Partnerships Obtained within the Past Few Months

GlobeNewswire September 19, 2017

Pulmatrix to Present at the Rodman & Renshaw Global Investment Conference on September 11, 2017

PR Newswire September 8, 2017

12 Biggest Mid-Day Losers For Wednesday

Benzinga.com  September 6, 2017

Pulmatrix Licenses Inhaled COPD Drug PUR0200 to Vectura Group plc

PR Newswire September 6, 2017

Vectura Announces Major New Tiotropium Bromide PI Development Programme Accelerated Through Licensing of Pulmatrix Technology

Benzinga.com  September 6, 2017

Pulmatrix Receives Award from Cystic Fibrosis Foundation Therapeutics to Support Development of PUR1900 for the Treatment of Pulmonary Fungal Infections

PR Newswire September 5, 2017

Daily Technical Summary Reports on Biotech Stocks -- Paratek Pharma, Pulmatrix, Verastem, and Biostage

PR Newswire August 24, 2017

Pulmatrix Provides 2017 Company Year-to-Date Highlights and Q2 2017 Updated Financials

PR Newswire August 4, 2017